GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

bimekizumab   Click here for help

GtoPdb Ligand ID: 9411

Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Approved drug Immunopharmacology Ligand
bimekizumab is an approved drug (EMA (2021), FDA (2023))
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
Bioactivity Comments
Binds to human recombinant IL-17A/F heterodimer with a Kd of 0.116nM, and monkey (cynomolgus) IL-17F with Kd of ~1nM [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-17A Primary target of this compound Hs Antibody Binding 10.7 pKd - 1
⤷ pKd 10.7 (Kd 2.1x10-11 M) [1]
Description: Biacore assay using recombinant human IL-17A
IL-17F Primary target of this compound Hs Antibody Binding - - - 1
⤷ [1]